A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Solid Tumor Clinical Trial

Official title:

Safety, Tolerability, Pharmacokinetics, and Efficacy of RC148 in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors: an Open-Label, Multicenter, Phase I Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06016062
• Other study ID #: RC148-C001
• Status: Recruiting
• Phase: Phase 1
• Start date: September 14, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: RemeGen Co., Ltd.
• Contact: Jianming Fang, ph.D
• Phone: +8610-58075763
• Email: jianmingfang[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is to evaluate the safety, tolerability, maximum tolerated dose (MTD) / maximum administered dose (MAD), pharmacokinetics (PK), pharmacodynamics, immunogenicity and recommended Phase 2 dose (RP2D) of RC148 in participants with locally advanced unresectable or metastatic solid tumors.In addition, the preliminary anti-tumour efficacy of RC148 as single agent will be assessed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participant must be able to provide documented voluntary informed consent.

2. Male or female participants = 18 years.

3. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.

4. The expected survival period exceeds 12 weeks.

5. At least one target lesion that can be measured per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.(For patients with prior radiotherapy, radiotherapy-treated lesions may be considered target lesions if they are measurable according to RECIST v1.1 criteria and there is evidence of significant progression after radiotherapy)

6. Histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.

7. Participants agree to provide pre-treatment archived /biopsy tumour samples (8-10 tissue slides) for retrospective programmed cell death protein 1 (PD-1)Expression level and MSI/MMR status related tests.Tumor specimen for marker detection should be from the most recent timepoint before entering the trial. Only when archived samples cannot be obtained, the biopsy will be considered at screening. Fresh tumour biopsies will NOT be considered if significant risk procedures are required per the discretion of the Investigator.

8. Adequate bone marrow, liver, and renal function defined as:

• absolute neutrophil count (ANC) = 1.5 × 10^9/L,

• platelet = 100 × 10^9/L,

• haemoglobin = 90 g/L,

• serum total bilirubin = 1.5 × upper limit of normal (ULN),

• ALT, AST = 2.5 × ULN (= 5 × ULN when there is known liver metastasis),

• serum creatinine = 1.5 × ULN,

• International normalized ratio (INR) = 1.5 × ULN,

• Activated partial thromboplastin time (APTT) = 1.5 × ULN. Urinalysis results for urinary protein <++; Subjects for whom urine protein =++ by urine test strip at baseline A 24-hour urine collection should be performed and the amount of protein in the urine over a 24-hour period should be <1g;

9. Male or female subjects with fertility must agree to take effective contraceptive measures during the study period and within 6 months after the end of the last medication, such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine contraceptive device.

Exclusion Criteria:

1. Pregnant or lactating.

2. Diagnosed active hepatitis B infection (defined as positive of hepatitis B surface antigen (HBsAg) and hepatitis B deoxyribonucleic acid [DNA]=500IU/ml), active hepatitis C infection (defined as presence of hepatitis C ribonucleic acid [RNA]), and human immunodeficiency virus (HIV) infection (defined as positive HIV test) during the screening period.

3. Received live attenuated vaccination within 28 days prior to the first dose of RC148

4. Participant with a history of other acquired/congenital immunodeficiency diseases or organ transplantation.

5. Participant who received prior anti-PD-1, anti- programmed cell death protein ligand 1 (anti-PD-L1), anti-cytotoxic T lymphocyte-associated (CTLA)-4 or any other immunotherapy or immune-oncology agent within 28 days of commencing treatment with RC148 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy.

6. Participant who had participated in other clinical trials and received study drug within 4 weeks before the first administration of IP.

7. Allergic constitution or allergic to known research drug active ingredients or excipient.

8. Participant who are under the treatment of anticoagulant drugs (e.g., warfarin, apixaban, and heparin). Participants using prophylactic doses of heparin (e.g., low-molecular-weight heparins [LMWH]) are eligible in the study.

9. Participant undergo any anti-tumour therapy, including surgery, chemotherapy, radiotherapy and biological therapy within 4 weeks prior to the first administration of IP,or Chinese traditional medicine for an antitumor indication within 2 weeks prior to first drug administration, or palliative radiotherapy for bone/other solitary metastases within 2 weeks prior to the first administration of IP.

10. Previous adverse reactions resulting from previous anti-tumour therapies, which have not returned to Grade 0 or 1 according to NCI-CTCAE v5.0 (except alopecia) at screening.

11. There are clinical symptoms of fluid in the third space (e.g., large amounts of pleural fluid or ascites).

12. A clinically significant active infection judged by the investigator(IP begins 2 weeks after completion of anti-infective treatment).

13. Comorbidities that may seriously endanger the participant's safety or affect the completion of the study, such as gastrointestinal bleeding (within 4 weeks prior to the screening period), History of hemoptysis (single hemoptysis > 2.5 mL of bright red blood) within 4 weeks prior to screening,peptic ulcer (within 4 weeks prior to the screening period), intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, kidney failure,Severe esophagogastric fundic varices and uncontrolled diabetes.

14. QT interval corrected by Fridericia's formula (QTcF) interval > 450 ms( male) and (QTcF) interval > 470 ms( femal (based on the mean value of the triplicate screening electrocardiogram [ECG]); family or personal history of long/short QT syndrome; history of ventricular arrhythmia deemed clinically significant by the investigator, or currently receiving antiarrhythmic drug treatment, or implantation of arrhythmia defibrillation device.

15. Have experienced arterial/venous thromboembolic events, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism within 1 year prior to the initiation of study treatment;

16. History of myocardial infarction within 6 months prior to the screening period, severe or unstable angina pectoris, coronary or peripheral artery bypass grafting, heart failure = 3 (New York Heart Association), or uncontrolled hypertension.

17. Participants with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily) or other immunosuppressive medications within 2 weeks of first IP administration.

18. Participants with active central nervous system (CNS) metastases. Participants with treated CNS metastases are permitted on study if the CNS metastases have been clinically stable for at least 4 weeks prior to treatment initiation and baseline scans show no evidence of new or enlarged lesions and meanwhile participant does not have leptomeningeal disease.For Carcinomatous Meningitis, regardless of whether the clinical status is stable or not, they should be excluded;

19. Have undergone major surgeries within 4 weeks prior to study treatment and have not recovered yet;

20. History or presence of uncontrolled mental illness at the discretion of the Investigator, which may place the participant at increased risk of safety/tolerability issues.

21. The participant is, in the opinion of the investigator, expected to be non-compliant with critical trial procedures and is not willing or able to adhere to the trial requirements in the future.

22. Participants who are not appropriate for this clinical trial at the discretion of the investigator.

23. Previously received dual anti-tumor drugs targeting both VEGF/VEGFR and PD-1/PD-L1. tumor drugs;

24. Screening stage imaging shows tumor invasion of large blood vessels.

25. Other malignancies within 5 years prior to the start of study dosing, except:

malignancies that are expected to resolve with treatment (including, but not limited to, adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery)

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• RC148
RC148 is a bispecific antibody, targeting programmed death-1(PD-1) and Vascular endothelial growth factor(VEGF).

Locations

Country	Name	City	State
China	Jinan Central Hospital	Jinan	Shandong
China	Qilu Hospital of shangdong university	Jinan	Shangdong
China	Shandong Tumor Hospital	Jinan	Shandong
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose(MTD)/Maximum administered dose(MAD)	MTD/MAD based on number of Dose limiting toxicity (DLT)	Subjects will be treated and observed for DLT through the end of the first cycle (Days 1-28)
Primary	DLT	In the DLT evaluation window (observation period 1-28 days after the first administration), according to the NCI-CTCAE v5.0 grading standard, the investigator or the sponsor believes that toxic reaction which are reasonably related to RC148 treatment	28 days after first treatment
Primary	The incidence and severity of adverse events (AE)	Adverse events was assessed by investigator(s) according to NCI-CTCAE v5.0	From the day of ICF sign to 28/90 days after the day of the last treatment
Primary	Recommended Phase 2 dose(RP2D)	The RP2D may be selected as 1 dose level lower than the MTD and will be determined in discussion with the safety monitoring committee based on all available data	28 days or 1cycle
Secondary	Antitumor Activity of RC148 by Overall Response Rate(ORR)	Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)	15 months
Secondary	DCR	Disease Control Rate was defined as the percentage of participants with a CR or PR or stable disease(SD)	15 months
Secondary	DOR	Duration of response is the length of time that a tumor continues to respond to treatment without the cancer growing or spreading	15 months
Secondary	PFS	Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	15 months
Secondary	Pharmacokinetics (PK) parameter: Maximum concentration (Cmax)	Cmax will be derived from the PK blood samples collected.	15 months
Secondary	PK parameter: Time to maximum concentration (Tmax)	Tmax will be derived from the PK blood samples collecte	15 months
Secondary	PK parameter: Terminal or apparent terminal half-life (t1/2)	t1/2 will be derived from the PK blood samples collected.	15 months
Secondary	PK parameter: Area under the concentration-time curve (AUC)	AUC will be derived from the PK blood samples collected.	15 months
Secondary	PK parameter:Systemic clearance (CL)	CL will be derived from the PK blood samples collected.	15 months
Secondary	PK parameter: Mean residence time (MRT)	MRT will be derived from the PK blood samples collected.	15 months
Secondary	PK parameter: Vz	Vz will be derived from the PK blood samples collected.	15 months
Secondary	PK parameter: ?z	?z will be derived from the PK blood samples collected.	15 months
Secondary	Immunogenicity assessment	blood samples will be collected to test the presence anti-RC148 antibodies	15 months